Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR

This publication has 50 references indexed in Scilit:

• Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
  Clinical Cancer Research, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2004
• Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2
  International Journal of Cancer, 2003
• The ErbB receptors and their role in cancer progression
  Experimental Cell Research, 2003
• MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL Receptors
  Journal of Biological Chemistry, 2001
• NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
  The EMBO Journal, 2000
• Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity
  Biochemical and Biophysical Research Communications, 1999
• Safety and antitumor activity of recombinant soluble Apo2 ligand
  Journal of Clinical Investigation, 1999
• Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors
  Journal of Cellular Biochemistry, 1987